Director Debra Peattie retires from Inhibitor Therapeutics Board

Inhibitor Therapeutics, Inc.

Debra Peattie retired from Board effective June 1, 2022, to focus on other professional opportunities.
Retirement is not based on any disagreement with the company's operations, policies, or practices.
Compensation Committee determined Peattie retired in good standing; vested options may be held for full term.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Debra Peattie

Director

INTI · Inhibitor Therapeutics, Inc.

Effective: 2022-06-01
Filed: June 3, 2022, 7:59 PM ET

On and effective June 1, 2022, Debra Peattie, PhD, MBA gave notice to Inhibitor Therapeutics, Inc. (the “Company”) of her retirement from the Board of Directors of the Company (the “Board”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Debra Peattie retired as Director at Inhibitor Therapeutics, Inc..

Action: retired
Role: Director

Exact text from the filing

On and effective June 1, 2022, Debra Peattie, PhD, MBA gave notice to Inhibitor Therapeutics, Inc. (the “Company”) of her retirement from the Board of Directors of the Company (the “Board”).

View on SEC.gov

Inhibitor Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-167340

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.